Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelox for Elderly Patients With Community Acquired Pneumonia
NCT00665327Phase 4Completed
- Sponsor
- Bayer
- Start
- Nov 2002
- Primary completion
- Apr 2004
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, randomised trial of moxifloxacin in community acquired pneumonia (CAP) (2 arms), sponsored by Bayer. Primary endpoint: Incidence of a composite safety end point (including cardiac arrest, sustained and non-sustained ventricular tachycardia) at 72 hours. Started Nov 2002; status: completed.
02
Drugs
moxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00665327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665327.